These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 20532823)
21. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. Ibdah JA; Bennett MJ; Rinaldo P; Zhao Y; Gibson B; Sims HF; Strauss AW N Engl J Med; 1999 Jun; 340(22):1723-31. PubMed ID: 10352164 [TBL] [Abstract][Full Text] [Related]
22. Living on the edge: substrate competition explains loss of robustness in mitochondrial fatty-acid oxidation disorders. van Eunen K; Volker-Touw CM; Gerding A; Bleeker A; Wolters JC; van Rijt WJ; Martines AM; Niezen-Koning KE; Heiner RM; Permentier H; Groen AK; Reijngoud DJ; Derks TG; Bakker BM BMC Biol; 2016 Dec; 14(1):107. PubMed ID: 27927213 [TBL] [Abstract][Full Text] [Related]
23. Development and pathomechanisms of cardiomyopathy in very long-chain acyl-CoA dehydrogenase deficient (VLCAD(-/-)) mice. Tucci S; Flögel U; Hermann S; Sturm M; Schäfers M; Spiekerkoetter U Biochim Biophys Acta; 2014 May; 1842(5):677-85. PubMed ID: 24530811 [TBL] [Abstract][Full Text] [Related]
24. Evidence that Oxidative Disbalance and Mitochondrial Dysfunction are Involved in the Pathophysiology of Fatty Acid Oxidation Disorders. Ribas GS; Vargas CR Cell Mol Neurobiol; 2022 Apr; 42(3):521-532. PubMed ID: 32876899 [TBL] [Abstract][Full Text] [Related]
25. Mitochondrial fatty acid beta-oxidation in the human eye and brain: implications for the retinopathy of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Tyni T; Paetau A; Strauss AW; Middleton B; Kivelä T Pediatr Res; 2004 Nov; 56(5):744-50. PubMed ID: 15347768 [TBL] [Abstract][Full Text] [Related]
26. Electrophysiological Abnormalities in VLCAD Deficient hiPSC-Cardiomyocytes Can Be Improved by Lowering Accumulation of Fatty Acid Oxidation Intermediates. Knottnerus SJG; Mengarelli I; Wüst RCI; Baartscheer A; Bleeker JC; Coronel R; Ferdinandusse S; Guan K; IJlst L; Li W; Luo X; Portero VM; Ulbricht Y; Visser G; Wanders RJA; Wijburg FA; Verkerk AO; Houtkooper RH; Bezzina CR Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32276429 [TBL] [Abstract][Full Text] [Related]
27. Outcomes of mitochondrial long chain fatty acid oxidation and carnitine defects from a single center metabolic genetics clinic. Ambrose A; Sheehan M; Bahl S; Athey T; Ghai-Jain S; Chan A; Mercimek-Andrews S Orphanet J Rare Dis; 2022 Sep; 17(1):360. PubMed ID: 36109795 [TBL] [Abstract][Full Text] [Related]
28. Mouse models for disorders of mitochondrial fatty acid beta-oxidation. Schuler AM; Wood PA ILAR J; 2002; 43(2):57-65. PubMed ID: 11917157 [TBL] [Abstract][Full Text] [Related]
29. Tissue acylcarnitine status in a mouse model of mitochondrial β-oxidation deficiency during metabolic decompensation due to influenza virus infection. Tarasenko TN; Cusmano-Ozog K; McGuire PJ Mol Genet Metab; 2018 Sep; 125(1-2):144-152. PubMed ID: 30031688 [TBL] [Abstract][Full Text] [Related]
30. Strategies for correcting very long chain acyl-CoA dehydrogenase deficiency. Tenopoulou M; Chen J; Bastin J; Bennett MJ; Ischiropoulos H; Doulias PT J Biol Chem; 2015 Apr; 290(16):10486-94. PubMed ID: 25737446 [TBL] [Abstract][Full Text] [Related]
31. [Study of the inborn errors of mitochondrial fatty acid beta-oxidation deficiency]. Zhu JM; Yang Z Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Apr; 38(2):214-7. PubMed ID: 16617370 [TBL] [Abstract][Full Text] [Related]
32. Clinical aspects of short-chain acyl-CoA dehydrogenase deficiency. van Maldegem BT; Wanders RJ; Wijburg FA J Inherit Metab Dis; 2010 Oct; 33(5):507-11. PubMed ID: 20429031 [TBL] [Abstract][Full Text] [Related]
33. De novo fatty acid biosynthesis and elongation in very long-chain acyl-CoA dehydrogenase-deficient mice supplemented with odd or even medium-chain fatty acids. Tucci S; Behringer S; Spiekerkoetter U FEBS J; 2015 Nov; 282(21):4242-53. PubMed ID: 26284828 [TBL] [Abstract][Full Text] [Related]
34. The clinical manifestation of MCAD deficiency: challenges towards adulthood in the screened population. Schatz UA; Ensenauer R J Inherit Metab Dis; 2010 Oct; 33(5):513-20. PubMed ID: 20532824 [TBL] [Abstract][Full Text] [Related]
36. Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned? Bastin J; Bonnefont JP; Djouadi F; Bresson JL J Inherit Metab Dis; 2015 Mar; 38(2):371-2. PubMed ID: 25310995 [No Abstract] [Full Text] [Related]
37. Medium branched chain fatty acids improve the profile of tricarboxylic acid cycle intermediates in mitochondrial fatty acid β-oxidation deficient cells: A comparative study. Karunanidhi A; Van't Land C; Rajasundaram D; Grings M; Vockley J; Mohsen AW J Inherit Metab Dis; 2022 May; 45(3):541-556. PubMed ID: 35076099 [TBL] [Abstract][Full Text] [Related]
38. Structural basis for substrate fatty acyl chain specificity: crystal structure of human very-long-chain acyl-CoA dehydrogenase. McAndrew RP; Wang Y; Mohsen AW; He M; Vockley J; Kim JJ J Biol Chem; 2008 Apr; 283(14):9435-43. PubMed ID: 18227065 [TBL] [Abstract][Full Text] [Related]
39. Effect of heat stress and bezafibrate on mitochondrial beta-oxidation: comparison between cultured cells from normal and mitochondrial fatty acid oxidation disorder children using in vitro probe acylcarnitine profiling assay. Li H; Fukuda S; Hasegawa Y; Kobayashi H; Purevsuren J; Mushimoto Y; Yamaguchi S Brain Dev; 2010 May; 32(5):362-70. PubMed ID: 19589653 [TBL] [Abstract][Full Text] [Related]